Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors (original) (raw)

• Landis, S.H. et al. Cancer statistics, 1999. CA Cancer J. Clin. 49, 8–31 (1999).
  Article CAS PubMed Google Scholar
• Orth, K. et al. Genetic instability in human ovarian cancer cell lines. Proc. Natl. Acad. Sci. USA 91, 9495–9499 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Auersperg, N., Edelson, M.I., Mok, S.C., Johnson, S.W. & Hamilton, T.C. The biology of ovarian cancer. Semin. Oncol. 25, 281–304 (1998).
  CAS PubMed Google Scholar
• Harper, P., Marsh, D. & Zori, R. Current clinical practices for ovarian cancers. Semin. Oncol. 29, 3–6 (2002).
  Article CAS PubMed Google Scholar
• Husain, A. et al. Lisofylline sensitizes p53 mutant human ovarian carcinoma cells to the cytotoxic effects of cis-diamminedichloroplatinum (II). Gynecol. Oncol. 70, 17–22 (1998).
  Article CAS PubMed Google Scholar
• Joenje, H. & Patel, K.J. The emerging genetic and molecular basis of Fanconi anaemia. Nat. Rev. Genet. 2, 446–457 (2001).
  Article CAS PubMed Google Scholar
• Taniguchi, T. & D'Andrea, A.D. The Fanconi anemia protein, FANCE, promotes the nuclear accumulation of FANCC. Blood 100, 2457–2462 (2002).
  Article CAS PubMed Google Scholar
• Pace, P. et al. FANCE: the link between Fanconi anaemia complex assembly and activity. EMBO J. 21, 3414–3423 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Medhurst, A.L., Huber, P.A., Waisfisz, Q., de Winter, J.P. & Mathew, C.G. Direct interactions of the five known Fanconi anaemia proteins suggest a common functional pathway. Hum. Mol. Genet. 10, 423–429 (2001).
  Article CAS PubMed Google Scholar
• Garcia-Higuera, I. et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell 7, 249–262 (2001).
  Article CAS PubMed Google Scholar
• Taniguchi, T. et al. Convergence of the Fanconi anemia and ataxia telangiectasia signaling pathways. Cell 109, 459–472 (2002).
  Article CAS PubMed Google Scholar
• Howlett, N.G. et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297, 606–609 (2002).
  CAS PubMed Google Scholar
• Shimamura, A. et al. A novel diagnostic screen for defects in the Fanconi anemia pathway. Blood 100, 4649–4654 (2002).
  Article CAS PubMed Google Scholar
• de Winter, J.P. et al. The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM. Nat. Genet. 24, 15–16 (2000).
  Article CAS PubMed Google Scholar
• Esteller, M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21, 5427–5440 (2002).
  Article CAS PubMed Google Scholar
• Jones, P.A. & Laird, P.W. Cancer epigenetics comes of age. Nat. Genet. 21, 163–167 (1999).
  Article CAS PubMed Google Scholar
• Andrews, P.A. & Albright, K.D. Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells. Cancer Res. 52, 1895–1901 (1992).
  CAS PubMed Google Scholar
• Krop, I.E. et al. HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. Proc. Natl. Acad. Sci. USA 98, 9796–9801 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Provencher, D.M. et al. Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell. Dev. Biol. Anim. 36, 357–361 (2000).
  Article CAS Google Scholar
• Wilson, A.P. Characterization of a cell line derived from the ascites of a patient with papillary serous cystadenocarcinoma of the ovary. J. Natl. Cancer Inst. 72, 513–521 (1984).
  CAS PubMed Google Scholar
• Rahman, N. & Stratton, M.R. The genetics of breast cancer susceptibility. Annu. Rev. Genet. 32, 95–121 (1998).
  Article CAS PubMed Google Scholar
• Esteller, M. et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst. 92, 564–569 (2000).
  Article CAS PubMed Google Scholar
• Hedenfalk, I. et al. Gene-expression profiles in hereditary breast cancer. N. Engl. J. Med. 344, 539–548 (2001).
  Article CAS PubMed Google Scholar
• Geisler, J.P., Hatterman-Zogg, M.A., Rathe, J.A. & Buller, R.E. Frequency of BRCA1 dysfunction in ovarian cancer. J. Natl. Cancer Inst. 94, 61–67 (2002).
  Article CAS PubMed Google Scholar
• Hilton, J.L. et al. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J. Natl. Cancer Inst. 94, 1396–1406 (2002).
  Article CAS PubMed Google Scholar
• Brown, R. et al. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 15, 45–52 (1997).
  Article CAS PubMed Google Scholar
• Strathdee, G., MacKean, M.J., Illand, M. & Brown, R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18, 2335–2341 (1999).
  Article CAS PubMed Google Scholar
• Plumb, J.A., Strathdee, G., Sludden, J., Kaye, S.B. & Brown, R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 60, 6039–6044 (2000).
  CAS PubMed Google Scholar
• Fogh, J., Wright, W.C. & Loveless, J.D. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58, 209–214 (1977).
  Article CAS PubMed Google Scholar
• Hamilton, T.C. et al. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 43, 5379–5389 (1983).
  CAS PubMed Google Scholar
• Hills, C.A. et al. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br. J. Cancer 59, 527–534 (1989).
  Article CAS PubMed PubMed Central Google Scholar
• Rauh-Adelmann, C. et al. Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines. Mol. Carcinog. 28, 236–246 (2000).
  Article CAS PubMed Google Scholar
• Kiguchi, K. et al. Selection of human ovarian carcinoma cells with high dissemination potential by repeated passage of the cells in vivo into nude mice, and involvement of Le(x)-determinant in the dissemination potential. Jpn. J. Cancer Res. 89, 923–932 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Schilder, R.J. et al. Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int. J. Cancer 45, 416–422 (1990).
  Article CAS PubMed Google Scholar
• Lewis, A.D., Hayes, J.D. & Wolf, C.R. Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects. Carcinogenesis 9, 1283–1287 (1988).
  Article CAS PubMed Google Scholar
• Kupfer, G.M., Naf, D., Suliman, A., Pulsipher, M. & D'Andrea, A.D. The Fanconi anaemia proteins, FAA and FAC, interact to form a nuclear complex. Nat. Genet. 17, 487–490 (1997).
  Article CAS PubMed Google Scholar
• Yamashita, T., Barber, D.L., Zhu, Y., Wu, N. & D'Andrea, A.D. The Fanconi anemia polypeptide FACC is localized to the cytoplasm. Proc. Natl. Acad. Sci. USA 91, 6712–6716 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Timmers, C. et al. Positional cloning of a novel Fanconi anemia gene, FANCD2. Mol. Cell 7, 241–248 (2001).
  Article CAS PubMed Google Scholar
• Siddique, M.A., Nakanishi, K., Taniguchi, T., Grompe, M. & D'Andrea, A.D. Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells. Exp. Hematol. 29, 1448–1455 (2001).
  Article CAS PubMed Google Scholar
• Garcia-Higuera, I., Kuang, Y., Naf, D., Wasik, J. & D'Andrea, A.D. Fanconi anemia proteins FANCA, FANCC, and FANCG/XRCC9 interact in a functional nuclear complex. Mol. Cell. Biol. 19, 4866–4873 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Ory, D.S., Neugeboren, B.A. & Mulligan, R.C. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc. Natl. Acad. Sci. USA 93, 11400–11406 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Kuang, Y. et al. Carboxy terminal region of the Fanconi anemia protein, FANCG/XRCC9, is required for functional activity. Blood 96, 1625–1632 (2000).
  CAS PubMed Google Scholar
• Naf, D., Kupfer, G.M., Suliman, A., Lambert, K. & D'Andrea, A.D. Functional activity of the Fanconi anemia protein FAA requires FAC binding and nuclear localization. Mol. Cell. Biol. 18, 5952–5960 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Yang, Y. et al. Targeted disruption of the murine Fanconi anemia gene, Fancg/Xrcc9. Blood 98, 3435–3440 (2001).
  Article CAS PubMed Google Scholar
• Herman, J.G., Graff, J.R., Myohanen, S., Nelkin, B.D. & Baylin, S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 93, 9821–9826 (1996).
  Article CAS PubMed PubMed Central Google Scholar